论文部分内容阅读
目的:评价经膀胱内灌注吡柔比星联合羟基喜树碱治疗尿道膀胱肿瘤电切术(TUR-BT)后复发的疗效。方法:126例浅表性膀胱癌术后患者随机分为THP组、HCPT组及联合用药组。采用不同的给药方法,观察各组复发率、不良反应等。结果:联合用药组复发率及不良反应均显著低于THP组和HCPT组。结论:THP和HCPT联合给药对于膀胱癌的术后复发疗效明显,不良反应少,值得临床推广使用。
OBJECTIVE: To evaluate the efficacy of intravesical instillation of pirarubicin combined with hydroxycamptothecin for the treatment of recurrent urethral bladder tumor (TUR-BT). Methods: 126 cases of superficial bladder cancer patients were randomly divided into THP group, HCPT group and combination group. Different administration methods were used to observe the relapse rate and adverse reactions in each group. Results: The relapse rate and adverse reactions in combination group were significantly lower than those in THP group and HCPT group. Conclusion: The combination therapy of THP and HCPT has obvious curative effect on postoperative recurrence of bladder cancer with less adverse reactions, which is worthy of clinical promotion.